Global Tofacitinib 麻豆原创 Insights, Forecast to 2030

Publication ID:

PB512245051

Publication Date:

December 25, 2024

Pages:

Publisher:

MRRPB5

Countries:

Global [1]

USD 4,900.00

Healthcare [2]

Pharma & Healthcare [3]

Description:

The global Tofacitinib market is projected to grow from US$ million in 2024 to US$ million by 2030, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.
The US & Canada market for Tofacitinib is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.
The China market for Tofacitinib is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.
The Europe market for Tofacitinib is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.
The global key manufacturers of Tofacitinib include Pfizer, Globe Pharmaceuticals, Delta Pharma Limited, Beacon Pharmaceuticals and Drug International, etc. In 2023, the global top five players had a share approximately % in terms of revenue.
Report Covers:
This report presents an overview of global market for Tofacitinib, sales, revenue and price. Analyses of the global market trends, with historic market revenue/sales data for 2019 - 2023, estimates for 2024, and projections of CAGR through 2030.
This report researches the key producers of Tofacitinib, also provides the sales of main regions and countries. Highlights of the upcoming market potential for Tofacitinib, and key regions/countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Tofacitinib sales, revenue, market share and industry ranking of main manufacturers, data from 2019 to 2024. Identification of the major stakeholders in the global Tofacitinib market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type, and by Application, sales, revenue, and price, from 2019 to 2030. Evaluation and forecast the market size for Tofacitinib sales, projected growth trends, production technology, application and end-user industry.
麻豆原创 Segmentation
By Company
Delta Pharma Limited
Beacon Pharmaceuticals
Drug International
Segment by Type
5mg*60 Tablets
5mg*10 Tablets
10mg*10 Tablets
5mg*30 Tablets
5mg*14 Tablets
10mg*14 Tablets
Segment by Application
Rheumatoid Arthritis
Ulcerative Colitis
Psoriasis
Others
Segment by Region
US & Canada
U.S.
Canada
China
Asia (excluding China)
Japan
South Korea
China Taiwan
Southeast Asia
India
Europe
Germany
France
U.K.
Italy
Russia
Latin America, Middle East & Africa
Brazil
Mexico
Turkey
Israel
GCC Countries
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, and by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Sales (consumption), revenue of Tofacitinib in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 3: Detailed analysis of Tofacitinib manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: North America (US & Canada) by Type, by Application and by country, sales, and revenue for each segment.
Chapter 7: Europe by Type, by Application and by country, sales, and revenue for each segment.
Chapter 8: China by Type, and by Application, sales, and revenue for each segment.
Chapter 9: Asia (excluding China) by Type, by Application and by region, sales, and revenue for each segment.
Chapter 10: Middle East, Africa, and Latin America by Type, by Application and by country, sales, and revenue for each segment.
Chapter 11: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Tofacitinib sales, revenue, price, gross margin, and recent development, etc.
Chapter 12: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.
Chapter 13: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 14: The main points and conclusions of the report.

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Study Coverage
1.1 Tofacitinib Product Introduction
1.2 麻豆原创 by Type
1.2.1 Global Tofacitinib 麻豆原创 Size Growth Rate by Type, 2019 VS 2023 VS 2030
1.2.2 5mg*60 Tablets
1.2.3 5mg*10 Tablets
1.2.4 10mg*10 Tablets
1.2.5 5mg*30 Tablets
1.2.6 5mg*14 Tablets
1.2.7 10mg*14 Tablets
1.3 麻豆原创 by Application
1.3.1 Global Tofacitinib 麻豆原创 Size Growth Rate by Application, 2019 VS 2023 VS 2030
1.3.2 Rheumatoid Arthritis
1.3.3 Ulcerative Colitis
1.3.4 Psoriasis
1.3.5 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Executive Summary
2.1 Global Tofacitinib Sales Estimates and Forecasts 2019-2030
2.2 Global Tofacitinib Revenue by Region
2.2.1 Global Tofacitinib Revenue by Region: 2019 VS 2023 VS 2030
2.2.2 Global Tofacitinib Revenue by Region (2019-2024)
2.2.3 Global Tofacitinib Revenue by Region (2025-2030)
2.2.4 Global Tofacitinib Revenue 麻豆原创 Share by Region (2019-2030)
2.3 Global Tofacitinib Sales Estimates and Forecasts 2019-2030
2.4 Global Tofacitinib Sales by Region
2.4.1 Global Tofacitinib Sales by Region: 2019 VS 2023 VS 2030
2.4.2 Global Tofacitinib Sales by Region (2019-2024)
2.4.3 Global Tofacitinib Sales by Region (2025-2030)
2.4.4 Global Tofacitinib Sales 麻豆原创 Share by Region (2019-2030)
2.5 US & Canada
2.6 Europe
2.7 China
2.8 Asia (excluding China)
2.9 Middle East, Africa and Latin America
3 Competition by Manufactures
3.1 Global Tofacitinib Sales by Manufacturers
3.1.1 Global Tofacitinib Sales by Manufacturers (2019-2024)
3.1.2 Global Tofacitinib Sales 麻豆原创 Share by Manufacturers (2019-2024)
3.1.3 Global Top 10 and Top 5 Largest Manufacturers of Tofacitinib in 2023
3.2 Global Tofacitinib Revenue by Manufacturers
3.2.1 Global Tofacitinib Revenue by Manufacturers (2019-2024)
3.2.2 Global Tofacitinib Revenue 麻豆原创 Share by Manufacturers (2019-2024)
3.2.3 Global Top 10 and Top 5 Companies by Tofacitinib Revenue in 2023
3.3 Global Key Players of Tofacitinib, Industry Ranking, 2022 VS 2023 VS 2024
3.4 Global Tofacitinib Sales Price by Manufacturers
3.5 Analysis of Competitive Landscape
3.5.1 Manufacturers 麻豆原创 Concentration Ratio (CR5 and HHI)
3.5.2 Global Tofacitinib 麻豆原创 Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.6 Global Key Manufacturers of Tofacitinib, Manufacturing Base Distribution and Headquarters
3.7 Global Key Manufacturers of Tofacitinib, Product Offered and Application
3.8 Global Key Manufacturers of Tofacitinib, Date of Enter into This Industry
3.9 Mergers & Acquisitions, Expansion Plans
4 麻豆原创 Size by Type
4.1 Global Tofacitinib Sales by Type
4.1.1 Global Tofacitinib Historical Sales by Type (2019-2024)
4.1.2 Global Tofacitinib Forecasted Sales by Type (2025-2030)
4.1.3 Global Tofacitinib Sales 麻豆原创 Share by Type (2019-2030)
4.2 Global Tofacitinib Revenue by Type
4.2.1 Global Tofacitinib Historical Revenue by Type (2019-2024)
4.2.2 Global Tofacitinib Forecasted Revenue by Type (2025-2030)
4.2.3 Global Tofacitinib Revenue 麻豆原创 Share by Type (2019-2030)
4.3 Global Tofacitinib Price by Type
4.3.1 Global Tofacitinib Price by Type (2019-2024)
4.3.2 Global Tofacitinib Price Forecast by Type (2025-2030)
5 麻豆原创 Size by Application
5.1 Global Tofacitinib Sales by Application
5.1.1 Global Tofacitinib Historical Sales by Application (2019-2024)
5.1.2 Global Tofacitinib Forecasted Sales by Application (2025-2030)
5.1.3 Global Tofacitinib Sales 麻豆原创 Share by Application (2019-2030)
5.2 Global Tofacitinib Revenue by Application
5.2.1 Global Tofacitinib Historical Revenue by Application (2019-2024)
5.2.2 Global Tofacitinib Forecasted Revenue by Application (2025-2030)
5.2.3 Global Tofacitinib Revenue 麻豆原创 Share by Application (2019-2030)
5.3 Global Tofacitinib Price by Application
5.3.1 Global Tofacitinib Price by Application (2019-2024)
5.3.2 Global Tofacitinib Price Forecast by Application (2025-2030)
6 US & Canada
6.1 US & Canada Tofacitinib 麻豆原创 Size by Type
6.1.1 US & Canada Tofacitinib Sales by Type (2019-2030)
6.1.2 US & Canada Tofacitinib Revenue by Type (2019-2030)
6.2 US & Canada Tofacitinib 麻豆原创 Size by Application
6.2.1 US & Canada Tofacitinib Sales by Application (2019-2030)
6.2.2 US & Canada Tofacitinib Revenue by Application (2019-2030)
6.3 US & Canada Tofacitinib 麻豆原创 Size by Country
6.3.1 US & Canada Tofacitinib Revenue by Country: 2019 VS 2023 VS 2030
6.3.2 US & Canada Tofacitinib Sales by Country (2019-2030)
6.3.3 US & Canada Tofacitinib Revenue by Country (2019-2030)
6.3.4 US
6.3.5 Canada
7 Europe
7.1 Europe Tofacitinib 麻豆原创 Size by Type
7.1.1 Europe Tofacitinib Sales by Type (2019-2030)
7.1.2 Europe Tofacitinib Revenue by Type (2019-2030)
7.2 Europe Tofacitinib 麻豆原创 Size by Application
7.2.1 Europe Tofacitinib Sales by Application (2019-2030)
7.2.2 Europe Tofacitinib Revenue by Application (2019-2030)
7.3 Europe Tofacitinib 麻豆原创 Size by Country
7.3.1 Europe Tofacitinib Revenue by Country: 2019 VS 2023 VS 2030
7.3.2 Europe Tofacitinib Sales by Country (2019-2030)
7.3.3 Europe Tofacitinib Revenue by Country (2019-2030)
7.3.4 Germany
7.3.5 France
7.3.6 U.K.
7.3.7 Italy
7.3.8 Russia
8 China
8.1 China Tofacitinib 麻豆原创 Size
8.1.1 China Tofacitinib Sales (2019-2030)
8.1.2 China Tofacitinib Revenue (2019-2030)
8.2 China Tofacitinib 麻豆原创 Size by Application
8.2.1 China Tofacitinib Sales by Application (2019-2030)
8.2.2 China Tofacitinib Revenue by Application (2019-2030)
9 Asia (excluding China)
9.1 Asia Tofacitinib 麻豆原创 Size by Type
9.1.1 Asia Tofacitinib Sales by Type (2019-2030)
9.1.2 Asia Tofacitinib Revenue by Type (2019-2030)
9.2 Asia Tofacitinib 麻豆原创 Size by Application
9.2.1 Asia Tofacitinib Sales by Application (2019-2030)
9.2.2 Asia Tofacitinib Revenue by Application (2019-2030)
9.3 Asia Tofacitinib Sales by Region
9.3.1 Asia Tofacitinib Revenue by Region: 2019 VS 2023 VS 2030
9.3.2 Asia Tofacitinib Revenue by Region (2019-2030)
9.3.3 Asia Tofacitinib Sales by Region (2019-2030)
9.3.4 Japan
9.3.5 South Korea
9.3.6 China Taiwan
9.3.7 Southeast Asia
9.3.8 India
10 Middle East, Africa and Latin America
10.1 Middle East, Africa and Latin America Tofacitinib 麻豆原创 Size by Type
10.1.1 Middle East, Africa and Latin America Tofacitinib Sales by Type (2019-2030)
10.1.2 Middle East, Africa and Latin America Tofacitinib Revenue by Type (2019-2030)
10.2 Middle East, Africa and Latin America Tofacitinib 麻豆原创 Size by Application
10.2.1 Middle East, Africa and Latin America Tofacitinib Sales by Application (2019-2030)
10.2.2 Middle East, Africa and Latin America Tofacitinib Revenue by Application (2019-2030)
10.3 Middle East, Africa and Latin America Tofacitinib Sales by Country
10.3.1 Middle East, Africa and Latin America Tofacitinib Revenue by Country: 2019 VS 2023 VS 2030
10.3.2 Middle East, Africa and Latin America Tofacitinib Revenue by Country (2019-2030)
10.3.3 Middle East, Africa and Latin America Tofacitinib Sales by Country (2019-2030)
10.3.4 Brazil
10.3.5 Mexico
10.3.6 Turkey
10.3.7 Israel
10.3.8 GCC Countries
11 Company Profiles
11.1 Pfizer
11.1.1 Pfizer Company Information
11.1.2 Pfizer Overview
11.1.3 Pfizer Tofacitinib Sales, Price, Revenue and Gross Margin (2019-2024)
11.1.4 Pfizer Tofacitinib Product Model Numbers, Pictures, Descriptions and Specifications
11.1.5 Pfizer Recent Developments
11.2 Globe Pharmaceuticals
11.2.1 Globe Pharmaceuticals Company Information
11.2.2 Globe Pharmaceuticals Overview
11.2.3 Globe Pharmaceuticals Tofacitinib Sales, Price, Revenue and Gross Margin (2019-2024)
11.2.4 Globe Pharmaceuticals Tofacitinib Product Model Numbers, Pictures, Descriptions and Specifications
11.2.5 Globe Pharmaceuticals Recent Developments
11.3 Delta Pharma Limited
11.3.1 Delta Pharma Limited Company Information
11.3.2 Delta Pharma Limited Overview
11.3.3 Delta Pharma Limited Tofacitinib Sales, Price, Revenue and Gross Margin (2019-2024)
11.3.4 Delta Pharma Limited Tofacitinib Product Model Numbers, Pictures, Descriptions and Specifications
11.3.5 Delta Pharma Limited Recent Developments
11.4 Beacon Pharmaceuticals
11.4.1 Beacon Pharmaceuticals Company Information
11.4.2 Beacon Pharmaceuticals Overview
11.4.3 Beacon Pharmaceuticals Tofacitinib Sales, Price, Revenue and Gross Margin (2019-2024)
11.4.4 Beacon Pharmaceuticals Tofacitinib Product Model Numbers, Pictures, Descriptions and Specifications
11.4.5 Beacon Pharmaceuticals Recent Developments
11.5 Drug International
11.5.1 Drug International Company Information
11.5.2 Drug International Overview
11.5.3 Drug International Tofacitinib Sales, Price, Revenue and Gross Margin (2019-2024)
11.5.4 Drug International Tofacitinib Product Model Numbers, Pictures, Descriptions and Specifications
11.5.5 Drug International Recent Developments
12 Industry Chain and Sales Channels Analysis
12.1 Tofacitinib Industry Chain Analysis
12.2 Tofacitinib Key Raw Materials
12.2.1 Key Raw Materials
12.2.2 Raw Materials Key Suppliers
12.3 Tofacitinib Production Mode & Process
12.4 Tofacitinib Sales and 麻豆原创ing
12.4.1 Tofacitinib Sales Channels
12.4.2 Tofacitinib Distributors
12.5 Tofacitinib Customers
13 麻豆原创 Dynamics
13.1 Tofacitinib Industry Trends
13.2 Tofacitinib 麻豆原创 Drivers
13.3 Tofacitinib 麻豆原创 Challenges
13.4 Tofacitinib 麻豆原创 Restraints
14 Key Findings in The Global Tofacitinib Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer

Companies Mentioned:

Pfizer
Globe Pharmaceuticals
Delta Pharma Limited
Beacon Pharmaceuticals
Drug International

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.